{"filings":[{"id":1417124,"accession_number":"0001815776-26-000046","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2026-07-02T21:00:28+00:00","items":["5.02"],"status":"ready","headline":"Director Zach Scheiner resigns from LENZ Therapeutics board; Jeff George appointed to audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zach Scheiner resigned from the Board and all committees effective June 30, 2026.","Resignation was not due to any dispute or disagreement with the company.","Board size reduced from seven to six members following the resignation.","Jeff George appointed to Audit Committee; members now Thunen, Guerard, and George."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027356,"accession_number":"0001815776-26-000041","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2026-06-12T20:08:05+00:00","items":["5.07"],"status":"ready","headline":"LENZ Therapeutics shareholders elect three Class II directors and ratify auditor at 2026 annual meeting.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Votes for Evert Schimmelpennink: 20,216,637; withheld: 230,219; broker non-votes: 3,995,212.","Votes for Jeff George: 13,462,359; withheld: 6,984,497; broker non-votes: 3,995,212.","Votes for Shelley Thunen: 20,215,686; withheld: 231,170; broker non-votes: 3,995,212.","Ratification of Ernst & Young as auditor passed: 24,310,915 for, 55,181 against, 75,972 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12961,"accession_number":"0001815776-26-000035","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2026-05-11T20:07:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.","Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.","Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.","Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.","Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026."],"consensus_eps_estimate":-1.0905,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1901000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108962,"accession_number":"0001815776-26-000008","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.","Net loss $35.9M ($1.16 per share) for Q4 2025 vs $12.7M in Q4 2024; cash $292.3M at year-end.","Over 6,500 unique prescribers in Q4, on pace for 10,000+ through Q1 2026; >55% wrote multiple times.","Sales force expanding from 88 to 117 territories in Q2 2026; MAA submitted to EMA in March 2026.","Launched 'Make it VIZZable' DTC campaign with Sarah Jessica Parker; website traffic up 10x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108961,"accession_number":"0001815776-26-000003","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.","Over 6,500 unique eye care professionals prescribed VIZZ; more than 55% prescribed multiple times in Q4.","VIZZ launched October 2025; broad retail and epharmacy access achieved by mid-November 2025.","Announced fourth international commercialization partnership with Lunatus for Middle East with milestones and revenue share."],"consensus_eps_estimate":-0.9906,"consensus_eps_actual":-2.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":19088000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125413,"accession_number":"0001815776-25-000077","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LENZ Therapeutics addresses FAERS report of retinal tear in VIZZ patient with pre-existing risk factors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.","Patient had significant retinal pathology history: lattice degeneration, prior laser, previous tear; no recent peripheral exam.","Independent retina specialists note multiple pre-existing risk factors making spontaneous retinal events more likely.","Company states this initial report does not alter current safety expectations for VIZZ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125412,"accession_number":"0001815776-25-000069","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics Q3 2025 net loss $16.7M; VIZZ launch with 5K+ prescriptions in October","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.7M ($0.59/share) vs $10.2M in Q3 2024; R&D spend down to $3.8M.","SG&A expenses surged to $27.6M ($6.5M Q3 2024) from commercial launch infrastructure.","Pro forma cash $324M after $123.5M ATM raise in Oct 2025, extending runway to post-launch cash flow positive.","VIZZ (aceclidine) launched Oct 2025 with >2,500 unique prescribers and >5,000 prescriptions filled through Oct.","Partnered with Sarah Jessica Parker for DTC campaign starting Q1 2026; Canada deal with Théa worth >$70M in milestones."],"consensus_eps_estimate":-0.7204,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":17500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125411,"accession_number":"0001815776-25-000064","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LENZ Therapeutics raises ~$80M via block trade of 1.75M shares at $45.75/shr","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,748,634 shares at $45.75/share for gross proceeds of ~$80M to a single investor.","Transaction executed as a block trade under April 2025 ATM Sales Agreement with TD Securities.","No stated use of proceeds or change in guidance from the capital raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142148,"accession_number":"0001815776-25-000062","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.","Professional sample distribution to optometrists and ophthalmologists initiated nationwide.","Commercial product shipments to consumers via ePharmacy starting October; broad availability by mid-Q4 2025.","93% of Phase 3 CLARITY trial participants achieved 20/40 near vision within 30 minutes, lasting up to 10 hours.","Addresses ~128 million U.S. adults with blurry near vision; CEO calls it a 'Category of One'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142147,"accession_number":"0001815776-25-000059","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.","First and only aceclidine-based eye drop; once-daily dosing with proven efficacy up to 10 hours.","Samples and commercial availability expected as early as October 2025; sales activities to begin immediately.","Approval based on three Phase 3 studies (CLARITY 1,2,3) showing rapid onset within 30 min and consistent near-vision improvement.","Well-tolerated; most common adverse reactions were instillation site irritation, dim vision, headache, mostly mild and self-resolving."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142146,"accession_number":"0001815776-25-000054","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.","Net loss $14.9M ($0.53 per share) for Q2 2025 vs $10.3M ($0.40) in Q2 2024.","NDA for LNZ100 (aceclidine for presbyopia) under FDA review; PDUFA target Aug 8, 2025; no advisory committee.","Commercial team of 88 sales force hired and trained; launch ready upon FDA approval.","Executed multiple international license deals totaling >$195M potential milestones plus double-digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160132,"accession_number":"0001815776-25-000036","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LENZ Therapeutics annual meeting elects directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17,983,676 of 27,544,520 shares represented at June 10, 2025 annual meeting.","Class III directors Kimberlee C. Drapkin and Zach Scheiner elected with ~12.4M and ~12.7M votes for.","Class I directors Frederic Guerard and James McCollum elected with ~15.4M and ~15.4M votes for.","Ernst & Young LLP ratified as independent auditor for FY2025 with 17,979,770 votes for.","No proposals or business items beyond standard director elections and auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160131,"accession_number":"0001815776-25-000030","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics Q1 net loss $14.6M; LNZ100 PDUFA on track for Aug 8, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M ($0.53 per share) vs $16.6M ($3.53) YoY; R&D down to $5.8M, SG&A up to $11.1M.","Cash $194.1M at Mar 31, 2025; anticipated balance >$185M at PDUFA; runway to post-launch positive cash flow.","NDA for LNZ100 (aceclidine eye drop for presbyopia) on track; FDA PDUFA target date Aug 8, 2025.","US Customs rulings confirm LNZ100 US origin and duty free, eliminating tariff exposure.","Pre-commercial hiring of 88 sales reps targeted by Jul 1, 2025; raised $16.3M net from April ATM block trade."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160130,"accession_number":"0001815776-25-000025","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","7.01","8.01"],"status":"ready","headline":"LENZ Therapeutics reports $194M cash as of March 31; holds Commercial Day for LNZ100 launch preparations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.","Hosting Commercial Day on April 15, 2025, focusing on potential approval and launch of LNZ100.","Presentation includes commercialization strategies, supply chain readiness, and KOL perspectives.","Cash figure is preliminary and subject to completion of financial closing procedures.","No other financial results or guidance were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160129,"accession_number":"0001628280-25-016824","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"LENZ Therapeutics enters into $150M ATM sales agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Sales Agreement with TD Securities (USA) LLC to sell up to $150M common stock via ATM offering.","TD Cowen will act as sales agent and receive up to 3.0% of gross proceeds from shares sold.","Shares will be issued under shelf registration statement on Form S-3 filed April 4, 2025.","Company has no obligation to sell shares and may suspend offerings at any time.","Agreement can be terminated by either party on 10 days' notice or immediately under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178445,"accession_number":"0001815776-25-000017","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.","Cash, cash equivalents & marketable securities $209.1M; cash runway expected to post-launch positive operating cash flow.","FY2024 net loss $49.8M ($2.34/share) vs FY2023 net loss $70.0M ($35.71/share).","R&D expenses fell to $29.8M in FY2024 from $59.5M in FY2023 as Phase 3 CLARITY study concluded.","SG&A expenses rose to $28.8M in FY2024 from $12.9M in FY2023 due to pre-commercial buildout for potential LNZ100 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195108,"accession_number":"0001815776-24-000069","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.","Cash, equivalents and marketable securities $217.2M as of Sept 30, 2024; cash runway to post-launch positive operating cash flow.","FDA accepted NDA for LNZ100 (aceclidine) for presbyopia; PDUFA target action date Aug 8, 2025.","Positive topline Phase 3 data from China: 74% of patients achieved 3-line or greater improvement at 3 hours (p<0.0001).","Completed $30M private placement with Ridgeback Capital in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195107,"accession_number":"0001815776-24-000064","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LENZ Therapeutics announces positive Phase 3 data for LNZ100 in China presbyopia trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 74% achieved ≥3-line improvement at 3 hours (p<0.0001 vs vehicle).","Rapid onset: 69% achieved ≥3-line improvement at 30 minutes; 84% achieved ≥2-line improvement.","Long duration: 30% maintained ≥3-line improvement at 10 hours; 61% achieved ≥2-line improvement.","No serious treatment-related adverse events observed; well-tolerated in 300-patient study.","LNZ100 is aceclidine-based eye drop; NDA already accepted by FDA for U.S. market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211394,"accession_number":"0001815776-24-000058","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics files NDA for LNZ100, reports Q2 net loss $10.3M, raises $30M via PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA submitted to FDA for LNZ100 aceclidine eye drop for presbyopia, supported by positive Phase 3 CLARITY data.","Q2 net loss $10.3M ($0.40/share) vs $14.7M ($7.53) in Q2 2023; R&D expenses fell to $6.9M from $12.6M.","Cash, equivalents and securities $196.2M; pro forma after July $30M Ridgeback PIPE, $226.2M, expected to fund to post-launch positive cash flow.","Phase 3 CLARITY: LNZ100 71% achieved 3-line near vision improvement at 3 hours, 40% at 10 hours, well-tolerated over 30,000 patient days.","SG&A expenses rose to $7.4M from $2.3M on pre-commercial planning and public company costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211393,"accession_number":"0001815776-24-000053","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LENZ submits NDA for LNZ100 (aceclidine) to FDA for presbyopia treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA supported by Phase 3 CLARITY study: met all primary and secondary near vision endpoints.","LNZ100 is an aceclidine-based eye drop targeting presbyopia, affecting ~1.8B people globally.","No serious treatment-related adverse events observed over 30,000 study days.","FDA has 60-day filing review period to determine NDA completeness for acceptance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211392,"accession_number":"0001815776-24-000049","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.","Proceeds to support regulatory and commercial launch activities for LNZ100, a presbyopia eye drop.","NDA submission for LNZ100 planned mid-2024; Phase 3 CLARITY data cited as strong.","Ridgeback Capital founder Dr. Wayne Holman expressed support; shares unregistered with resale registration to be filed.","Existing cash plus PIPE proceeds to fund pre-commercial and potential launch activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230018,"accession_number":"0001815776-24-000039","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LENZ Therapeutics reports Q1 net loss $16.6M; positive Phase 3 presbyopia data, NDA on track mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.","Phase 3 CLARITY study for LNZ100 met all primary/secondary endpoints; 84% achieved ≥4 lines near vision improvement.","NDA submission to FDA for LNZ100 planned for mid-2024; commercial launch as early as H2 2025.","Completed merger with Graphite Bio and concurrent $53.5M private placement in March 2024.","Jeff George appointed Chairman; Dan Chevallard CFO; commercial buildout underway including third-party logistics."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230017,"accession_number":"0001815776-24-000035","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).","Rapid onset: 71% achieved ≥3-line improvement at 30 minutes; long duration: 40% at 10 hours.","No serious treatment-related adverse events in >30,000 treatment days across three trials.","LNZ100 selected as lead candidate; company plans NDA submission to FDA in mid-2024.","Patient survey: 90% reported near vision improvement; 75% would continue use post-study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248462,"accession_number":"0001628280-24-012633","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.01","3.02","4.01","9.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Graphite Bio completes reverse merger with LENZ Therapeutics, rebrands as LENZ, raises $53.5M PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger closed March 21, 2024; Graphite renamed LENZ Therapeutics, Inc., ticker changes from GRPH to LENZ on March 22.","Reverse stock split 1:7 effective; post-merger shares outstanding ~25.5M, plus 164,676 warrants and 1.59M options.","New company focuses on presbyopia treatment; Phase 3 CLARITY top-line results for LNZ100/LNZ101 expected April 2024.","NDA submission planned mid-2024; product launch targeted for second half of 2025 if FDA approved.","PIPE financing of $53.5M closed concurrently; audited FY2023/2022 financials of LENZ OpCo included as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248461,"accession_number":"0001193125-24-071353","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Graphite Bio stockholders approve 1:7 reverse split, name change to LENZ; effective March 21, trading as LENZ March 22","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved 1-for-7 reverse stock split and name change to 'LENZ Therapeutics, Inc.' at March 14 special meeting.","Reverse split and name change effective 4:01 p.m. ET March 21, 2024; no fractional shares, cash paid in lieu.","Common stock trades on split-adjusted basis under ticker 'LENZ' from March 22, 2024; new CUSIP 52635N103.","Proportional adjustments made to outstanding equity awards and shares reserved under stock plans.","Actions taken in connection with pending merger with LENZ Therapeutics; merger closing expected thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248460,"accession_number":"0001193125-24-067966","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Graphite Bio shareholders approve all merger-related proposals for Lenz deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (stock issuance and control change) passed: 40.9M for, 37k against, 7.5M broker non-votes.","Proposal 2 (reverse split 1:6–1:12 and name change to LENZ Therapeutics) passed: 48.3M for, 170k against.","Proposal 3 (2024 Equity Incentive Plan) passed: 36.6M for, 4.4M against, 7.5M broker non-votes.","Proposal 4 (2024 Employee Stock Purchase Plan) passed: 37.3M for, 3.7M against, 7.5M broker non-votes.","Proposal 5 (adjournment) not presented; sufficient votes existed for Proposals 1 and 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248459,"accession_number":"0001193125-24-063785","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Graphite Bio declares special $1.03/share dividend tied to Lenz merger","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend estimated at $1.03 per share, capped at $60M.","Record date March 18, 2024; payment date March 21, 2024.","Dividend contingent on closing of merger with Lenz Therapeutics.","Graphite stockholders vote on merger at special meeting March 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248458,"accession_number":"0001193125-24-058513","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Graphite Bio discloses supplemental proxy details to resolve merger-related shareholder lawsuits","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two federal lawsuits filed in CA and DE allege proxy omissions on LENZ financials, advisor conflicts; 12 additional demand letters received.","Company voluntarily adds disclosures including Transaction Committee member compensation ($0 extra) and liquidation value of $2.86/sh in Feb 2024.","Liquidation analysis per share in March 2027: $0.10 low case, $0.19 high case based on $5.6M-$11.1M net cash.","Leerink DCF analysis yielded implied exchange ratio range of 2.8075-3.2957, valuing LENZ equity at $460M-$540M.","Graphite denies allegations, states proxy complies with law; no executive officers expected to serve in combined company post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265965,"accession_number":"0001193125-23-303051","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.","Merger with Lenz Therapeutics, previously announced Nov. 14, 2023, remains subject to stockholder approval and other conditions.","Closing will result in Lenz becoming a wholly owned subsidiary of Graphite; combined company intends to list on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265964,"accession_number":"0001193125-23-277555","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Graphite Bio to merge with Lenz Therapeutics; Lenz holders to own 65%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Graphite valued at $126.5M, LENZ at $231.6M; $60M cash dividend to pre-merger Graphite stockholders.","LENZ stockholders will own ~65% of combined company, Graphite ~35% on fully-diluted basis.","Concurrent PIPE investment of $53.5M (minimum $50M, up to $125M) to close alongside merger.","Post-merger board: 7 members (5 from LENZ, 2 from Graphite); company renamed LENZ Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265963,"accession_number":"0000950170-23-056341","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Graphite Bio subleases 32,113 SF to Soleil Labs, terminates master lease by Dec 2024 with ~$36.7M in payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subleases 32,113 sq ft of its 85,165 sq ft facility to Soleil Labs for $183,044/mo (first 12 mos) then $189,451/mo, term through Dec 31, 2024.","Enters First Amendment to Lease to terminate Master Lease on Dec 31, 2024; pays $15.9M prepaid rent and $20.8M termination fee.","Surrenders all furniture and equipment to landlord upon termination; landlord returns letter of credit within 60 days.","Company will have no further rent obligations post-Effective Date; Landlord may further accelerate termination for remaining space at $20K/month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283182,"accession_number":"0000950170-23-047925","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K/A","filed_at":"2023-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Graphite Bio amends CEO Josh Lehrer's separation agreement with consulting and equity acceleration terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation agreement dated Sept 7, 2023 provides Tier 1 severance benefits under Executive Severance Plan.","Lehrer to serve as consultant for up to 12 months or until a Strategic Transaction closes.","Equity awards continue vesting during consulting; acceleration if Strategic Transaction within 6 months.","If Strategic Transaction within 3 months, Lehrer receives enhanced benefits as if termination during Change in Control.","Strategic Transaction defined broadly: merger, sale, reverse merger, or Sale Event under 2021 Stock Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283185,"accession_number":"0000950170-23-044135","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["8.01","2.05","5.02"],"status":"ready","headline":"Graphite Bio appoints new CEO, cuts 70% of workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kimberlee C. Drapkin appointed President & CEO, effective Aug 21, 2023; base salary $550,000.","Board approved a restructuring plan reducing workforce by approximately 70%.","Estimated severance and related costs of ~$1.6 million, recorded primarily in Q3 2023.","Former CEO Josh Lehrer separated; entitled to Tier 1 severance and retention benefits.","Company continues exploring strategic alternatives as part of corporate restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283184,"accession_number":"0000950170-23-037141","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Graphite Bio appoints Kimberlee Drapkin as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11; Drapkin appointed effective July 28, 2023.","Drapkin has 25+ years biotech/pharma experience; formerly CFO at Jounce Therapeutics.","She will receive cash and equity under Director Compensation Policy, prorated from appointment.","No arrangements or family relationships with other directors or executive officers.","She serves on boards of Acumen Pharmaceuticals, Imugene, and Kineta."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283183,"accession_number":"0000950170-23-033594","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Graphite Bio shareholders elect three Class II directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Abraham Bassan, Matthew Porteus, and Jo Viney elected with >35.8M votes each; 5.6M broker non-votes.","Deloitte & Touche ratified as FY2023 auditor: 44,039,995 for, 11,869 against, 55,188 abstentions.","Total shares entitled to vote: 58,102,949; shares present/proxy: 44,107,052."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302586,"accession_number":"0000950170-23-029499","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Graphite Bio CFO Alethia Young resigns; CEO Josh Lehrer to assume PFO/PAO roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alethia Young resigns as CFO, effective June 30, 2023, to pursue other opportunities.","Resignation not related to any disagreement with the company or its management.","CEO Josh Lehrer appointed as Principal Financial Officer and Principal Accounting Officer effective July 1, 2023.","Dr. Lehrer has served as CEO since April 2020; prior roles at Global Blood Therapeutics and Genentech.","Ms. Young will remain through June 30 to ensure orderly transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322248,"accession_number":"0000950170-23-008761","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Graphite Bio discontinues sickle cell gene therapy nula-cel, begins strategic review, reports FY2022 net loss $101.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.","Initiated process to evaluate strategic alternatives; corporate restructuring to preserve capital while conducting review.","FY2022 net loss $101.1M ($1.84/share); cash and equivalents $283.6M as of Dec 31, 2022.","Voluntarily paused Phase 1/2 CEDAR study of nula-cel in Jan 2023 due to treatment-related pancytopenia.","Intends to continue research on early-stage non-genotoxic conditioning program toward potential development candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322247,"accession_number":"0000950170-23-008443","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Graphite Bio enters retention agreements with senior management amid strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.","50% acceleration of unvested equity awards granted in 2023 on qualifying termination after June 30, 2023.","Stock option exercise period extended to 12 months post-termination or original expiry.","Strategic alternatives process is ongoing; retention agreements designed to retain key talent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322246,"accession_number":"0000950170-23-003808","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Graphite Bio discontinues sickle cell gene therapy nula-cel, cuts workforce 50%, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues development of nula-cel for sickle cell disease; exploring external continuation.","Reduces workforce by approximately 50%; expects severance costs of ~$4.9M in Q2 2023.","Chief Business Officer and Chief Scientific Officer to depart in Q2 2023.","Preliminary unaudited cash, equivalents, and marketable securities of ~$283.5M as of Dec 31, 2022.","Will continue early-stage non-genotoxic conditioning program; board approved restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322245,"accession_number":"0000950170-23-000228","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Graphite Bio pauses Phase 1/2 sickle cell gene therapy study after serious adverse event in first patient","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First patient dosed with nula-cel experienced prolonged pancytopenia requiring ongoing transfusion and growth factor support.","Company will not meet guidance for initial proof-of-concept data in mid-2023; IND for GPH102 in beta-thalassemia delayed beyond mid-2024.","Company working to identify operational efficiencies to extend cash runway to at least 2026; will provide business update by end of Q1 2023.","Patient achieved neutrophil engraftment with no evidence of myelodysplasia; event reported to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340298,"accession_number":"0000950170-22-026333","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Graphite Bio presents preclinical data for sequencing method to measure gene editing outcomes in sickle cell","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data presented at ASH on single-cell RNA sequencing method to assess gene correction in reticulocytes.","Method accurately differentiated AA, AS, and SS reticulocytes in proof-of-concept mixtures.","Method will be used to measure gene editing outcomes in patients treated with nula-cel (GPH101) for sickle cell disease.","Nula-cel is being evaluated in the CEDAR Phase 1/2 trial with Fast Track and Orphan Drug designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340297,"accession_number":"0000950170-22-023837","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.","Q3 net loss $24.7M ($0.45 per share); R&D expenses $18.3M, G&A $7.9M.","Cash, equivalents and investments $305.1M as of Sep 30, 2022; runway into Q4 2024.","Entered strategic manufacturing partnership with WuXi Advanced Therapies for nula-cel.","Two abstracts accepted for ASH 2022; hired Darren Hart as SVP of development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340296,"accession_number":"0000950170-22-021600","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.","Abstract #3468 (poster) details single-cell RNA sequencing method to assess gene-editing outcomes in sickle cell disease.","CEO Josh Lehrer notes initial proof-of-concept data for nula-cel (SCD therapy) expected mid-2023.","Nula-cel is a first-in-human gene correction therapy; FDA granted Fast Track and Orphan Drug designations.","ASH meeting takes place Dec 10-13, 2022 in New Orleans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357571,"accession_number":"0000950170-22-016857","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.","Cash, cash equivalents and marketable securities of $328.3M as of June 30, 2022; cash runway into Q4 2024.","Q2 2022 net loss of $25.9M ($0.48 per share); R&D expenses $17.8M, G&A $9.0M.","Nula-cel received FDA Fast Track designation for SCD; also has Orphan Drug designation.","Preclinical data for GPH102 in beta-thalassemia presented at ASGCT; IND planned by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357570,"accession_number":"0000950170-22-016657","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Graphite Bio doses first patient with nula-cel for sickle cell disease; proof-of-concept data mid-2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.","Nula-cel is a gene editing therapy designed to directly correct the SCD mutation and restore healthy hemoglobin.","Initial proof-of-concept data from the CEDAR trial expected in mid-2023.","FDA granted Fast Track and Orphan Drug designations for nula-cel.","Phase 1/2 trial to enroll ~15 patients with severe SCD at multiple U.S. sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357569,"accession_number":"0001193125-22-192923","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K/A","filed_at":"2022-07-13T23:59:59+00:00","items":["8.01","2.02","9.01"],"status":"ready","headline":"Graphite Bio reports GPH102 preclinical HDR rates up to 40% in sickle cell HSPCs; IND planned mid-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GPH102 gene replacement achieved homology directed repair (HDR) rates up to 40% in sickle cell HSPCs and restored adult hemoglobin (HbA) expression.","Company plans to submit an IND for GPH102 in beta-thalassemia by mid-2024, pending regulatory feedback.","An encore trial-in-progress poster for GPH101 Phase 1/2 CEDAR trial in sickle cell disease was also presented at ASGCT.","GPH102 uses UltraHDR platform to replace mutated beta-globin gene, targeting >300 mutations that cause beta-thalassemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376156,"accession_number":"0001193125-22-180184","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Graphite Bio stockholders elect three Class I directors and ratify auditor at 2022 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Jerel Davis, Perry Karsen, and Joseph Jimenez as Class I directors; each received >37M votes for, ~3M withheld.","Ratification of Deloitte & Touche as independent auditor for FY2022 passed with ~42.2M for, 5,230 against, 9,929 abstentions.","Total shares present or represented: 42,241,989 out of 57,970,110 shares entitled to vote.","Broker non-votes: 1,680,515 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376155,"accession_number":"0001564590-22-020233","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.","GPH102 aims to replace mutated beta-globin gene to treat beta-thalassemia, targeting IND submission by mid-2024.","Encore poster for GPH101 Phase 1/2 CEDAR trial for sickle cell disease also presented at ASGCT.","Data accepted for encore presentation at EHA 2022 Hybrid Congress in June."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376154,"accession_number":"0001564590-22-019849","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.","Cash, equivalents and investments $352.1M as of March 31, 2022; runway into Q4 2024.","GPH101 for sickle cell disease received FDA Fast Track Designation; first patient dosing target H2 2022, proof-of-concept data in 2023.","GPH102 for beta-thalassemia preclinical data presented at ASGCT; IND submission expected by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394516,"accession_number":"0001564590-22-011122","cik":1815776,"company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.","FY2021 net loss $70.8M ($2.45/share); Q4 net loss $18.9M ($0.35/share).","GPH101 Phase 1/2 CEDAR trial: first patient dosing now H2 2022 (COVID-19 impact); initial data 2023.","New programs: GPH102 for beta-thalassemia (IND mid-2024) and early AAT deficiency program.","Appointed Alethia Young as CFO, Christine Garrett as Chief of Staff/SVP Ops; promoted Julia Tran to CPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":250208071.73868045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-21T23:59:59+00:00|394516"}